Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Mycoses. 2020 Jan;63(1):58-64. doi: 10.1111/myc.13013. Epub 2019 Oct 30.

Abstract

In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Keywords: Aspergillus; invasive aspergillosis; isavuconazole; posaconazole; voriconazole.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / therapeutic use
  • Aspergillosis / drug therapy*
  • Cohort Studies
  • Female
  • Humans
  • Invasive Fungal Infections / drug therapy
  • Male
  • Middle Aged
  • Nitriles / adverse effects
  • Nitriles / therapeutic use
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Treatment Outcome
  • Triazoles / adverse effects
  • Triazoles / therapeutic use*
  • Voriconazole / therapeutic use

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole
  • posaconazole
  • Voriconazole